ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

FDA News: ODAC Clears Photofrin For Microinvasive NSCLC

September 26, 1997

Information Branches Combined Under ICIC, Moved to Office Of NCI Deputy Director

November 23, 1997

Bush Administration proposes 2.7 percent increase for NIH in fiscal year 2005; NIH budgets listed by institute.

February 6, 2004

Study Finds Gene Expression Test Predicts Stage I or II Recurrence

August 30, 2013

In Brief: MB Ends Apportionment Carlo Croce To Head Fels Institute, Replacing Peter Magee Sept. 1

March 4, 1988

NCAB Votes Down Effort to Delay CCOP RFA, Directs Subcommittee To Look Again A Program Components

February 12, 1982